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Background: To examine the association of anthropometry indices with gout and to compare the performance of
indices to predict gout in Taiwanese men.
Methods: There were 1443 male subjects aged more than 20 years who participated in the Nutrition and Health
Survey in Taiwan (NAHSIT, 1993–1996). Anthropometric evaluation consisted of weight, height, hip and waist
circumference (WC) with later body mass index (BMI), waist to height (WHtR) and waist to hip (WHR) estimations.
We conducted 4 logistic models to determine the relationships between anthropometric indices and gout. Receiver
operating characteristic (ROC) curve were used to compare the predictive performance and to identify the optimal
cut-off points, sensitivity and specificity of these indices for gout in men.
Results: After controlling for other covariables, the adjusted odds ratios for the mid and top tertiles of WHtR were
2.55 (95% CI: 1.16, 5.59) and 3.01 (95% CI: 1.13, 7.99), respectively, but no linear association was found for BMI, WHR
and WC. In ROC curve, the greatest area under curve was 0.684 for WHtR and the cut-off point of WHtR was 0.57.
Conclusions: WHtR had a significant linear association with gout in Taiwanese men and was superior to BMI, WHR
and WC.
Keywords: Gout, Anthropometry, Waist to height ratioBackground
The prevalence of gout has increased in recent years [1].
Twenty-six percent of adult males (≥19 years) and 22%
of older males (≥45 years) either had hyperuricemia or
were taking medication for it in Nutrition and Health
Survey in Taiwan (NAHSIT, 1993–1996) [2]. The data
from the Taiwan National Health Insurance Research
Database showed that the prevalence of gout was 4.26%
and male to female ratio was 3.2:1 [3]. Subjects with
high serum uric acid levels are at higher risk for all-
cause and cardiovascular mortality [4]. Gout increases
the risk of cardiovascular disease, even in young people
and those without cardiovascular risk factors [5]. Gout
also increases mortality risk in both genders, especially* Correspondence: Liawyp@csmu.edu.tw
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and cardiovascular diseases [6].
Overweight and obesity are epidemic and obese people
often have hyperuricemia. Increased serum uric acid [7]
and gout occurrence [8] have been known to be closely as-
sociated with an increase in visceral fat accumulation. The
significance of visceral fat obesity has been found to be
associated with chronic metabolic disorders [9]. Insulin re-
sistance plays a key role in the connection between hyper-
uricemia and metabolic syndrome [10,11]. It is known that
body mass index (BMI), triglycerides, hypertension, inflam-
mation and insulin resistance increase the uric acid con-
centration [12-14]. High plasma urate concentration is
associated with articular deposits of urate crystals that
cause gout [15]. The predisposing factors such as alcohol
consumption, diuretics use, and excess weight gain in-
crease risks of gout attack among patients with hyperurice-
mia [16]. Gout has also been linked with metabolic
syndrome and diabetes [17]. Obesity is positively associated
with gout, whereas body weight loss is protective [18].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographic, clinical, laboratory and







Age (year) 55.1 ± 13.7 51.1 ± 15.7 0.01
Area (%) <0.01
Hakka area 13.5 14.3
Mountainous area 37.5 13.7
East Coast area 9.6 15.3
Penghu islands 10.6 14.0
Metropolitan cities 9.6 14.9
Provincial class I townships 10.6 13.1
Provincial class II townships 8.7 14.7
Lifestyle factors
Smoking (%) 68.6 70.9 0.63
Alcohol drinking (%)
Low 17.7 19.7 0.80
Moderate 54.9 51.6
High 27.5 28.7
Hypertension medication (%) 21.2 8.2 <0.01
Anthropometric indices
BMI (kg/m2) 25.2 ± 2.9 23.5 ± 3.4 <0.01
WC (cm) 86.3 ± 7.6 81.3 ± 9.8 <0.01
WHR 0.90 ± 0.05 0.87 ± 0.07 <0.01
WHtR 0.53 ± 0.04 0.49 ± 0.06 <0.01
Renal disease (%) 4.9 2.5 0.15
Metabolic syndrome (%) 41.4 16.9 <0.01
Triglyceride ≧ 150 mg/dl (%) 45.2 24.1 <0.01
HDL <40 mg/dl (%) 37.5 28.5 0.05
High blood pressure (%)* 71.2 53.6 0.01
High fasting glucose (%)# 15.4 12.0 0.31
Uric acid ≧ 7.0 mg/dl (%) 64.4 40.3 <0.01
Data are expressed as mean ± standard deviation, unless otherwise indicated.
Abbreviations: BMI Body mass index, HDL High density lipoprotein, WC Waist
circumference, WHR Waist to hip ratio, WHtR Waist to height ratio.
*Blood pressure ≧ 130/85 mmHg or participants with medication control.
# Fasting glucose ≧ 100 mg/dl or participants with medication control.
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to find an easy, practical screening index for predicting
gout in the general male Taiwanese population. However,
the evidence about the correlation of BMI, waist circum-
ference (WC), waist to hip ratio (WHR), or waist to height
ratio (WHtR) with gout in the Taiwanese population is
scant. We tried to assume that other anthropometric
index rather than BMI could more accurately predict gout.
Therefore, the aim of this study was to ascertain which




The data were obtained from the Nutrition and Health
Survey in Taiwan that was performed between 1993
and 1996 (NAHSIT, 1993–1996). NAHSIT was a na-
tionwide survey for the nutrition and health status of
Taiwanese. All instruments of the NAHSIT 1993–1996
were evaluated for validity and reliability in 3 pilot
studies conducted from January to June in 1993 [19].
All subjects were gave written informed consent for
participation before enrollment in the study. The data-
base consists of de-identified secondary data and is re-
leased for purposes of public researches.
The details of the design and the operational tech-
niques about the survey have been described previously
[20]. Briefly, data were drawn from 7 geographical dis-
trict samples according to their unique dietary patterns
of the residents, ancestral origins, geographic location,
and degree of urbanization (Hakka people areas, moun-
tainous areas, the East coast area, the Peng-Hu islands,
metropolitan cities, urbanization Class I townships, and
urbanization Class II townships).
Data collection
After the strata were classified, 3 townships or city dis-
tricts were selected within each stratum by selection prob-
ability proportional to its population size (PPS). Three
communities were selected in each township or city dis-
trict by PPS method. People in each communities were
further divided into 7 age groups (4–6, 7–12, 13–15, 16–
18, 19–44, 45–64, and ≧ 65 years) and 2 sex groups. Eight
or 16 individuals (depending on the available age groups)
were sampled in each age group by sex group. A pseudo-
Latin square design was used to allocate survey time to
balance the effects of season and year in this subtropical
land. Demographic and clinical characteristics, and phys-
ical examinations were recorded and documented during
face-to-face interviews with structured questionnaires. Fi-
nally, there were 6464 subjects completed the physical
examination and 5843 adequate fasting blood samples.
The present study enrolled 1443 Taiwanese males aged
≧20 years with complete questionnaires (sex, age, area,alcohol consumption, and medical history), physical ex-
aminations and results of fasting blood samples.
Definitions
Hyperuricemia was defined as serum uric acid ≧ 7.0 mg/dl
for males [21]. Taiwan definitions adopted BMI 24 kg/m2
as the cutpoint for overweight and 27 kg/m2 for obesity
[22]. The definitions of metabolic syndrome in males are
WC ≥90 cm and any two of the following: (1) high trigly-
ceride ≥150 mg/dL, (2) low HDL-cholesterol <40 mg, (3)
high blood pressure ≥130/85 mg or on medication, (4)
raised fasting plasma glucose ≧100 mg/dl or diabetes [23].
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ician from questionnaires.
The self-reported alcohol consumption was categorized
into low, moderate and high. Anthropometric variables in-
cluded height, weight, WC and hip circumference. Hip
circumference was measured at the level of the greater
trochanter. WC was measured at the mid-level between
the iliac crest and the last rib. BMI was calculated as
weight (kilogram) divided by height (meter) squared,
WHR was calculated as WC (centimeter) divided by HC
(centimeter), and WHtR was calculated as WC (centi-
meter) divided by height (centimeter).
Statistical analyses
All analyses were carried out by using the SAS ver. 9.1
software package (SAS Institute, Cary, NC, USA). Compar-
isons between gout and non-gout subjects’ demographic
data, laboratory measurements, and anthropometric indi-
ces were made using Student’s t test and Chi-square tests.
Adjusted odds ratios (ORs) with 95% confidence intervals
(CIs) for gout were calculated from the multiple logistic re-
gression analysis according to obesity (BMI ≥ 27 kg/m2 and
top tertile of WC, WHR, and WHtR) and the tertiles of
the indices. In the current study, the ROC curve analyses
were performed by calculating the true positive rate
(sensitivity) against the false-positive rate (1 − specificity) toTable 2 The ORs for gout in relation to obesity definitions aft
Variables Model 1
OR 95% CI OR
Hyperuricemia
No 1.00 1.00
Yes 1.90 (1.21, 3.00) 1.92
Renal disease
No 1.00 1.00
Yes 1.32 (0.46, 3.77) 1.36
Alcohol drinking
Low 1.00 1.00
Moderate 1.05 (0.58, 1.90) 1.07
High 0.83 (0.42, 1.65) 0.81
Metabolic syndrome
No 1.00 1.00
Yes 1.85 (1.14, 3.02) 1.84
Obesity*
WC (cm) ≧ 88.1 1.70 (1.04, 2.79)
WHR ≧ 0.91 1.77
WHtR ≧ 0.53
BMI (kg/m2) ≧ 27
Adjustment for age, smoking, areas and hypertension medication in all models.
Abbreviations: BMI Body mass index, WC Waist circumference, WHR Waist to hip rat
*Obesity is defined as BMI ≥ 27 kg/m2 and top tertile of WC,WHR, and WHtR.assess and measure the predictive power of each anthropo-
metric index in the association with gout based on the area
under the curve (AUC). A p value <0.05 was considered
statistically significant.
Results
The basic characteristics of the 104 gout and 1339 non-
gout male participants aged ≧ 20 years are shown in
Table 1. The age of gout group was older than non-gout
Taiwanese. The highest prevalence of gout was found in
the mountainous areas. The prevalence of high an-
thropometric indices, metabolic syndrome, dyslipidemia,
high blood pressure and hyperuricemia were signifi-
cantly higher in gout group than that in non-gout group.
There were no significant differences in smoking, alco-
hol drinking and renal disease between the two groups.
In Table 2, BMI ≥27 kg/m2 and the top tertile of WC,
WHR and WHtR were considered to be obese. It shows
the ORs for gout by BMI ≥ 27 kg/m2 and top tertile of
WC, WHR, and WHtR after adjusting for age, smoking,
areas and hypertension medications. Hyperuricemia and
metabolic syndrome were significantly associated with
gout in all models. The adjusted OR for gout was
significantly increased in the top tertile of WC (OR,
1.70; 95% CI, 1.04-2.79), WHR (OR, 1.77; 95% CI, 1.07-
2.92), and WHtR (OR, 2.28; 95% CI, 1.35-3.86). A non-er adjustment for potential confounders
Model 2 Model 3 Model 4
95% CI OR 95% CI OR 95% CI
1.00 1.00
(1.22, 3.02) 1.87 (1.19, 2.96) 1.92 (1.22, 3.02)
1.00 1.00
(0.48, 3.85) 1.31 (0.46, 3.74) 1.22 (0.43, 3.50)
1.00 1.00
(0.59, 1.92) 1.03 (0.57, 1.86) 1.08 (0.60, 1.95)
(0.41, 1.61) 0.81 (0.49, 1.62) 0.89 (0.45, 1.75)
1.00 1.00




io, WHtR Waist to height ratio.
Table 3 The ORs for gout in relation to tertiles of each anthropometric index after adjustment for potential
confounders
Variables Model 1 Model 2 Model 3 Model 4
OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Renal disease No 1.00 1.00 1.00 1.00
Yes 1.47 (0.51, 4.19) 1.55 (0.55, 4.39) 1.45 (0.51, 4.13) 1.43 (0.50, 4.10)
Alcohol drinking Low 1.00 1.00 1.00 1.00
Moderate 1.08 (0.60, 1.96) 1.09 (0.60, 1.97) 1.08 (0.59, 1.98) 1.10 (0.61, 2.00)
High 0.85 (0.42, 1.70) 0.82 (0.41, 1.65) 0.85 (0.42, 1.72) 0.88 (0.44, 1.77)
Metabolic disorders*
Hypertriglyceridemia No 1.00 1.00 1.00 1.00
Yes 1.70 (1.06, 2.72) 1.65 (1.03, 2.64) 1.64 (1.02, 2.63) 1.70 (1.06, 2.72)
Low HDL No 1.00 1.00 1.00 1.00
Yes 1.13 (0.72, 1.79) 1.11 (0.70, 1.75) 1.10 (0.70, 1.75) 1.13 (0.72, 1.79)
High blood pressure No 1.00 1.00 1.00 1.00
Yes 1.14 (0.69, 1.88) 1.14 (0.69, 1.87) 1.12 (0.68, 1.85) 1.11 (0.68, 1.84)
High fasting glucose No 1.00 1.00 1.00 1.00
Yes 0.78 (0.42, 1.45) 0.75 (0.40, 1.40) 0.78 (0.41, 1.46) 0.76 (0.41, 1.43)
Hyperuricemia No 1.00 1.00 1.00 1.00
Yes 1.78 (1.12, 2.85) 1.77 (1.11, 2.83) 1.78 (1.12, 2.85) 1.77 (1.11, 2.82)
WC (cm) <81.7 1.00 1.00 1.00 1.00
81.7-88.1 1.81 (1.04, 3.14) 1.47 (0.78, 2.75) 0.91 (0.42, 1.98) 1.52 (0.81, 2.86)
≧ 88.1 1.83 (1.06, 3.18) 1.38 (0.68, 2.81) 0.78 (0.31, 1.95) 1.35 (0.61, 2.99)
P trend 0.03 0.41 0.61 0.38
WHR <0.87 1.00
0.87-0.91 1.53 (0.81, 2.88)
≧ 0.91 1.57 (0.75, 3.26)
P trend 0.21
WHtR <0.49 1.00
0.49-0.53 2.55 (1.16, 5.59)
≧ 0.53 3.01 (1.13, 7.99)
P trend 0.03
BMI (kg/m2) <24 1.00
24-27 1.42 (0.76, 2.65)
≧ 27 1.50 (0.64, 3.51)
P trend 0.42
Adjustment for age, smoking, areas, and hypertension medication in all models.
Abbreviations: BMI Body mass index, HDL High density lipoprotein, WC Waist circumference, WHR Waist to hip ratio, WHtR Waist to height ratio.
*Hypertriglyceridemia: triglyceride ≧ 150 mg/dl; low HDL: HDL < 40 mg/dl; high blood pressure: blood pressure ≧ 130/85 mmHg or hypertension medication; high
fasting glucose: glucose ≧ 100 mg/dl or diabetic medication; hyperuricemia: uric acid ≧ 7.0 mg/dl.
Table 4 Estimated area under curve (AUC) of the indices in predicting gout in men
Index Estimated AUC 95% CI Optimal cut-point Sensitivity Specificity
WHtR 0.684 (0.639, 0.729) 0.57 0.67 0.67
BMI 0.659 (0.610, 0.708) 27.12 0.72 0.60
WHR 0.657 (0.608, 0.706) 0.89 0.71 0.62
WC 0.655 (0.607, 0.703) 94 0.69 0.64
Abbreviations: BMI Body mass index, WC Waist circumference, WHR Waist to hip ratio, WHtR Waist to height ratio.
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1.59; 95% CI, 0.98-2.57) in Model 4.
Four multivariable models of gout consisting of vari-
ables for renal disease, alcohol drinking, metabolic syn-
drome, hyperuricemia and anthropometric indices after
adjustment for age, smoking, areas and hypertension
medication are shown in Table 3. The OR for gout was
significantly increased in the mid and top tertiles of WC
in Model 1 (p trend = 0.03). We simultaneously adjusted
WC into the Model 2, 3, and 4. After the adjustments,
the ORs for gout increased significantly for WHtR, but
not for BMI and WHR. The adjusted odds ratios for the
mid and top tertiles of WHtR were 2.55 (95% CI: 1.16,
5.59) and 3.01 (95% CI: 1.13, 7.99) in Model 3, respect-
ively. The obesity index, WHtR, seemed to have more
stable effects on gout than did WC.
Table 4 shows the AUC values of WHtR, BMI, WHR,
and WC by using ROC analysis to detect the predictive
power of all anthropometric indices for gout. Of the 4 an-
thropometric indices, WHtR was found to have the largest
areas under the ROC curve (0.684). The best combination
of sensitivity and specificity for gout was 0.67 and 0.67, re-
spectively. The optimal cut-off values for gout showed
WHtR of 0.57.
Discussion
The proxy measures of visceral fat obesity, principally,
WC, WHR or WHtR are used as a surrogate of body fat
centralization and have been use for cardiovascular risk
evaluation because of their association with cardio-
metabolic parameters and outcome [9,24,25]. In 2001
Chang et al. [2] reported a nationwide survey from Taiwan
that showed strong associations of serum uric acid con-
centrations with mountainous area, age and BMI in
men. A cross-sectional study of 2023 military personnel
in Taiwan showed positive associations of serum uric
acid with BMI, systolic and diastolic blood pressure, and
dyslipidemia [26]. Villegas et al. investigated hyperu-
ricemia in a population consisting middle-aged, urban
Chinese men and identified graded positive associations
of BMI, WHR, WC, and weight gain [27]. A nationwide
study in Taiwan demonstrated that WC has the stron-
gest correlation with hyperuricemia for both men and
women than BMI and WHR [28].
In a community based epidemiological study in
Taiwan, the risk factors for gout among either the
general population or subjects with hyperuricemia
were serum uric acid level, alcohol drinking and cen-
tral obesity [21]. Hypertriglyceridemia in men may po-
tentiate the effect of serum uric acid to increase the
risk of gout development [29]. In a large prospective
cohort of men, higher BMI and weight gain are strong
risk factors for gout in men, while weight reduction is
protective [18].WHtR is a more practical anthropometric index to
find higher metabolic risks in normal and overweight
Japanese men and women than WC and BMI [30]. A
hospital based case–control study of 92 gout and 92
non-gout men showed that WHtR had a significant
linear effect on gout risk, independent of BMI [31]. In
our study, altered WC increased the chances of gout,
but this fact occurred only in the first adjustment of the
model in Table 3. When the BMI, WHR and WHtR sep-
arately were added, the effect of WC was lost. After
adjustment by WC, the OR of WHtR remained signifi-
cant. From our multivariable models, it suggested that
the index of central obesity, especially WHtR, was better
index for identifying the risk for gout in this population
than were WC and WHR.
One of the strengths of our study was the use of a
computerized database, which was population-based and
highly representative. A number of important limitations
warrant discussion. First, NAHSIT was a cross-sectional
study and susceptible to unmeasured confounders and
reverse causation. Second, as a result of modernization
and life style changes globally, the anthropometric vari-
ables of the studied population may have changed. The
results from data collected between 1993 and 1996 could
be established as a reference or model to which future
studies could compare. Third, the diagnosis of gout is
based on self reported diagnosis by a physician that
might be biased. Although gold standard diagnosis of
gout is based upon aspiration of joint fluid for the iden-
tification of urate crystals [32], it is impractical for epi-
demiologic research. Gout is often defined by self-report
in epidemiologic studies. Previous population-based co-
hort study suggested that the self-report of physician
diagnosed gout has good reliability and sensitivity and is
appropriate for epidemiologic studies [33].
Conclusion
We had confirmed the hypothesis that WHtR rather
than BMI could more accurately predict gout. Among
the 4 anthropometric indices used in the present study,
although higher values of WC, WHR, and WHtR were
associated with gout, WHtR appears to be an independ-
ent and better anthropometric index for identifying indi-
viduals with gout.
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